| Literature DB >> 13129583 |
Miyako Masubuchi1, Hirosato Ebiike, Ken-ichi Kawasaki, Satoshi Sogabe, Kenji Morikami, Yasuhiko Shiratori, Shinji Tsujii, Toshihiko Fujii, Kiyoaki Sakata, Michiko Hayase, Hidetoshi Shindoh, Yuko Aoki, Tatsuo Ohtsuka, Nobuo Shimma.
Abstract
The C-4 side chain modification of lead compound 1 has resulted in the identification of a potent and selective Candida albicans N-myristoyltransferase (CaNmt) inhibitor RO-09-4609, which exhibits antifungal activity against C. albicans in vitro. Further modification of its C-2 substituent has led to the discovery of RO-09-4879, which exhibits antifungal activity in vivo. The drug design is based on X-ray crystal analysis of a CaNmt complex with benzofuran derivative 4a. The optimization incorporates various biological investigations including a quasi in vivo assay and pharmacokinetic study. The computer aided drug design, synthesis, structure-activity relationships, and biological properties of RO-09-4879 are described in detail.Entities:
Mesh:
Substances:
Year: 2003 PMID: 13129583 DOI: 10.1016/s0968-0896(03)00429-2
Source DB: PubMed Journal: Bioorg Med Chem ISSN: 0968-0896 Impact factor: 3.641